Clinical Trial Update: Phase 1b of Lurbinectedin in Combination With Weekly Paclitaxel and Bevacizumab in Platinum-resistant Ovarian Cancer [Phase 1]

View source ↗

Summary

A Phase 1b trial is evaluating lurbinectedin in combination with weekly paclitaxel and bevacizumab for platinum-resistant ovarian cancer; the study is currently…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Bevacizumab (bevacizumab)
• Lurbinectedin (lurbinectedin)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Ovarian Cancer | Phase 1 | Status: RECRUITING